Greenleaf Trust Reduces Stake in Danaher Corporation $DHR

Key Points

• Greenleaf Trust has reduced its stake in Danaher Corporation by 9.3%, selling 8,671 shares during the second quarter, leaving it with 84,672 shares worth approximately $16.7 million.
• Danaher reported a Q2 earnings per share of $1.80, beating the consensus estimate of $1.64, while its quarterly revenue rose by 3.4% compared to the prior year.
• The company has announced a quarterly dividend of $0.32 per share, which represents an annualized yield of 0.7%.

Greenleaf Trust lowered its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 9.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,672 shares of the conglomerate's stock after selling 8,671 shares during the period. Greenleaf Trust's holdings in Danaher were worth $16,726,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Hills Bank & Trust Co lifted its stake in shares of Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after purchasing an additional 53 shares during the period. Worth Financial Advisory Group LLC grew its holdings in shares of Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate's stock worth $236,000 after purchasing an additional 53 shares during the period. Sageworth Trust Co grew its stake in Danaher by 2.3% during the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock worth $493,000 after buying an additional 54 shares during the period. 1834 Investment Advisors Co. increased its holdings in Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after purchasing an additional 54 shares in the last quarter. Finally, Bruce G. Allen Investments LLC grew its stake in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock valued at $92,000 after buying an additional 54 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Up 0.6%

Danaher stock opened at $185.87 on Tuesday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a market capitalization of $133.09 billion, a PE ratio of 39.55, a PEG ratio of 2.63 and a beta of 0.75. The business's 50-day simple moving average is $199.39 and its 200-day simple moving average is $197.30.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio is 27.23%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 11.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DHR. Wells Fargo & Company dropped their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Barclays reissued an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Bank of America cut their target price on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a report on Monday, September 22nd. Robert W. Baird raised their target price on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Finally, Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $245.91.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.